Peripheral immunochemical considerations in Parkinson disease: sources, targets and crosstalk mechanisms Authors: Alessandra Castegna, Luna Laera, Piergianni Moda, Stefano Miglietta, Mariagrazia D’Agostino, Melania Ruggiero, Antonia Cianciulli, Francesca Martina Filannino, Chiara Porro, D. Allan Butterfield, Maria Antonietta Panaro Published: 2026 ABSTRACT BackgroundParkinson disease is a progressive neurodegenerative disorder characterized by the degeneration of dopamine neurons in the substantia nigra pars compacta, leading to a broad spectrum of motor and non-motor symptoms. Increasing evidence indicates that chronic inflammation and immune dysregulation are central to its pathogenesis. The activation of microglia, astrocytes, and circulating monocytes establishes a self-perpetuating cycle of inflammation and neuronal injury, positioning monocytes as a key interface between systemic and central immune responses.Main textThe discovery of misfolded alpha-synuclein in peripheral tissues, such as the gut, olfactory mucosa and skin, supports a multisystem view of the disease, suggesting that peripheral pathology may precede and drive neurodegeneration through neuroanatomical and microbiota-mediated routes. Monocytes exhibit altered subset composition, impaired phagocytic capacity, and metabolic reprogramming involving mitochondrial and lysosomal dysfunction, partly linked to mutations in the LRRK2 and GBA1 genes, which further sustain inflammation and alpha-synuclein aggregation. In parallel, the disruption of the blood-brain and meningeal barriers facilitates immune cell infiltration and amplifies neuroinflammatory signalling within the brain. Elevated circulating cytokines, chemokines, and inflammasome activation reflect a primed immune state correlated with disease progression, whereas metabolic disturbances in tryptophan, purine, lipid, and microbiota-derived pathways connect peripheral metabolic imbalance to neuronal vulnerability. Finally, exosomes act as critical mediators of communication between the periphery and the brain. Owing to their ability to cross the blood-brain barrier bidirectionally, they contribute to the dissemination of alpha-synuclein and transport miRNAs that promote oxidative stress, two key mechanisms underlying Parkinson disease pathology. These features position exosomes as both promising targets for biomarker discovery and effective vehicles for the targeted delivery of therapeutic agents to the central nervous system.ConclusionsTogether, this review highlights peripheral inflammation and misfolded alpha-synuclein as pivotal contributors to neuroinflammatory mechanisms in Parkinson disease, emphasizing monocyte-related pathways as promising targets for disease monitoring and intervention. Introduction Parkinson disease (PD) is one of the most common neurodegenerative disorders and is characterized by the progressive degeneration of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc). This neurodegenerative process leads to a spectrum of motor manifestations, including resting tremor, rigidity, bradykinesia and postural instability, as well as a wide range of non-motor symptoms, such as cognitive impairment, autonomic dysfunction, depression, gastrointestinal disturbances and dementia [1–4]. Current therapies are largely symptomatic, relying primarily on dopaminergic replacement therapy, with levodopa still representing the most effective option for motor symptom control [5]. Although device-assisted strategies such as deep brain stimulation and continuous drug infusion improve advanced disease management, they do not modify the underlying neurodegenerative process. Emerging approaches, including antidiabetic drugs, gene therapy, and stem-cell-based treatments, show promise but are not yet disease-modifying or curative [5]. While motor symptoms remain the most recognized clinical hallmark, contemporary research has increasingly focused on the underlying molecular mechanisms. Current evidence identifies the synergistic interaction between alpha-synuclein (α-syn), microglia, and neuroinflammation as the primary contributors to disease progression. Preclinical and clinical research on PD suggests that immune system abnormalities play a significant role in the initiation and progression of the disease [6–9]. Epidemiological studies indicate that individuals prescribed specific immunosuppressive agents, such as corticosteroids and inosine monophosphate dehydrogenase inhibitors, exhibit a reduced risk of developing PD [10]. Furthermore, an elevated systemic immune-inflammation index (SII), calculated as the platelet count multiplied by the neutrophil count and divided by the lymphocyte count, is associated with an increased risk of PD in the adult population, suggesting that higher levels of systemic inflammation predict a greater likelihood of disease development [11]. Imaging studies in PD patients have shown early activation of microglia in the SNpc, which is believed to occur before substantial loss of DA neurons [12]. The subsequent release of cytokines, such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), and of reactive oxygen species (ROS) from microglia generates a harmful microenvironment in which reactive astrocytes acquire a neurotoxic A1 phenotype [8, 13–18]. Peripheral immune dysfunction is apparent in monocytes, T cells, and neutrophils, which exhibit irregular activity and lead to increased serum proinflammatory cytokine levels [19, 20]. Additionally, the expression of major histocompatibility complex class II (MHCII) molecules, especially HLA-DR, is elevated in microglia and peripheral monocytes and contributes, together with α-syn-specific peptides, to T-cell activation and neuroinflammation [21]. Monocyte-driven peripheral and central inflammation has been linked to PD neurodegeneration through the generation of IL-1β, IL-6, and TNF-α [22–24]. These alterations are also evident in genetic research [25, 26] and transcriptomic studies [23, 27] indicating that altering monocyte activation or inhibiting monocyte entry into the central nervous system (CNS) decreases neuroinflammation and provides neuroprotection in preclinical PD models [28, 29]. Together, this evidence supports a conceptual framework in which peripheral immune dysfunction conceivably actively contributes to PD initiation and progression. In this review, we expand on current neuroinflammatory concepts to highlight how inflammation can both initiate and sustain PD progression. In line with the idea that peripheral immune cells are not passive responders but function as key hubs linking systemic inflammation to central neurodegeneration, we propose that peripheral effects should be considered as mechanistic contributors to neuronal death in PD, as clinically accessible targets for biomarker development, and as potential therapeutic strategies to slow and hopefully halt its progression. By integrating evidence on inflammatory signalling, immune-metabolic dysfunction, microbiota-driven immune priming, barrier integrity and intercellular transfer mechanisms, we aim to delineate in this review how peripheral immunity shapes α-syn propagation and central neurodegeneration and to highlight translational opportunities arising from this immune-centric view of PD. Microgliosis and early signs of inflammation Although the pathogenic mechanisms of PD remain unclear, evidence suggests that there is a correlation between age, genetic background and the environment [30]. Numerous studies have shown that neuroinflammation plays a critical role in the development of this disease and can accelerate the progressive loss of DA neurons in the SN [31, 32]. In this context, the immune system of patients with PD presents a continuous inflammatory state, observable by changes in the lymphocyte subsets in the cerebrospinal fluid (CSF) and blood, as well as increased synthesis of cytokines, immunoglobulins and acute phase proteins [33]. Furthermore, brain neuroimaging studies in patients with PD have revealed pronounced microgliosis, as detected by positron emission tomography (PET) via the radioligand [18F]-FEPPA, which targets the translocator protein (TSPO) in microglial mitochondria [34, 35]. In the brain, glial cells and neurons continuously interact with each other and with the surrounding extracellular environment to maintain neuronal homeostasis; disruptions to these interactions can contribute to neurological disorders such as PD [36]. Microglial activation is a pathological feature common to several neurodegenerative diseases. During PD progression, microglia exhibit high plasticity, transitioning from a homeostatic surveillance state to various activation states that significantly influence DA-neuron survival. Although microglia are traditionally classified into two main polarization states, M1 and M2, these categories represent extremes of a broader phenotypic spectrum regulated by complex mechanisms and environmental cues. The M1 phenotype is strongly associated with chronic neuroinflammation and the progression of neurodegeneration. When cells lose their ramified structure, they adopt an amoeboid shape, which facilitates their migration toward lesion sites and enhances the phagocytosis of cellular debris. The M1 polarization state is characterized by the expression of CD86 antigen and inducible nitric oxide synthase (iNOS). M1 microglia actively release proinflammatory cytokines such as IL-1β, IL-12, and TNF-α. These substances, coupled with the production of ROS, exacerbate damage to DA neurons. The M2 microglial phenotype is associated with inflammation resolution and tissue repair. It features elongated cell bodies and highly ramified cytoplasmic processes. Primary markers include the mannose receptor (CD206) and arginase-1 (ARG-1). M2 microglia secrete anti-inflammatory cytokines, such as interleukins-4, -10 and -13 (IL-4, IL-10, and IL-13), transforming growth factor beta-1 (TGF-β1), and trophic factors like insulin like growth factor 1 (IGF-1), which help mitigating inflammation and support neuronal survival. The microglial phenotype is not static but undergoes drastic changes as PD advances. In very early stages, microglial activation occurs, probably to exert a neuroprotective function, attempting to maintain brain homeostasis. As pathology progresses, the homeostatic interaction between microglia and neurons breaks down. Activated microglia contribute to a vicious cycle: sustained microglial activation creates a detrimental inflammatory loop in both PD patients and animal models, leading to progressive DA neuron degeneration [37, 38]. Encoded in humans by the SNCA gene, α-syn is an abundant presynaptic protein primarily localized at the axon terminals and is physiologically involved in maintaining neurotransmission homeostasis. Originally isolated in 1988 from the torpedo electric organ for its association with synaptic vesicles and nuclear envelopes [39], the human 140-amino-acid homologue was later identified in the brain [40]. As a monomer, it plays a role in the regulation of synaptic vesicle trafficking, DA homeostasis, synaptic plasticity, and nuclear maintenance [41–43], with emerging evidence linking its activity to DNA repair mechanisms [44]. Although initially overlooked, α-syn gained major attention in 1997 with the identification of SNCA point mutations as a rare cause of autosomal dominant PD [45]. In the same year, insoluble intracellular inclusions known as Lewy bodies (LBs) and Lewy neurites (LNs) were shown to be highly immunoreactive for α-syn, identifying it as a core component of these aggregates [46]. The progressive aggregation of α-syn into insoluble amyloid fibrils within neurons or oligodendrocytes, which leads to the formation of insoluble LBs and LNs under oxidative stress, is now recognized as a defining feature of PD and other synucleinopathies, including multiple system atrophy [47–49]. The phosphorylation of α-syn at serine 129 (pSer129 syn) is a hallmark of PD pathology. Under physiological conditions, only a small fraction of α-syn is phosphorylated at this site. In contrast, in the brains of PD patients, this proportion increases dramatically, with pSer129 syn accounting for more than 90% of the protein localized within LBs [50, 51]. Phosphorylation alters the electrostatic charge of its C-terminal domain, increasing its propensity for conformational changes, thus facilitating the transition from soluble monomers to insoluble oligomers and fibrils, effectively acting as a catalyst for the protein aggregation cascade [52]. For these reasons, α-syn aggregates act as neurodegeneration-associated molecular patterns (NAMPs), a subset of endogenous danger signals specifically associated with the progression of neurodegenerative pathologies [53]. These patterns act as ligands for pattern recognition receptors (PRRs) expressed on the microglial surface, most notably Toll-like receptors 2 and 4 (TLR2 and TLR4) and triggering receptor expressed on myeloid cells 2 (TREM2) [54]. The activation of TLR2 and TLR4 is known to induce proinflammatory signalling cascades, leading to the production of cytokines such as TNF-α, thereby contributing to neuroinflammatory processes. α-Syn oligomers are capable of binding to lipids, destroying cell membrane integrity, and causing cell death both in vitro and in vivo [49]. Furthermore, aggregated α-syn present in LBs is known to induce M1 microglia activation, leading to the death of DA neurons [55]. Once activated, microglia undergo various morphological changes, such as the thickening and retraction of ramifications, the exposure of MHC I/II proteins, the expression of immune molecules, and the secretion of cytotoxic factors, recruitment molecules, and proinflammatory molecules, leading to a proinflammatory cascade [56], which is accompanied by increased proliferation [57, 58]. Although microglial activation is crucial for fighting infections or dealing with brain trauma, cellular damage subsequent to excessive activation has been proposed as a contributor to the degeneration of DA neurons in PD. High levels of inflammatory cytokines, such as TNF-α and IL-1β, observed in the SNpc, striatum, CSF and peripheral blood mononuclear cells (PBMCs) of idiopathic patients support this hypothesis [59]. The expression of the chemokine C-X-C motif chemokine ligand 10 (CXCL10), also known as interferon gamma-induced protein 10 (IP-10), has also been found to be elevated in the CSF of PD patients, and CXCL10 is a proposed marker associated with the microglial proinflammatory phenotype [59, 60]. α-Syn contributes to the abovementioned “vicious cycle” of microglia: the protein aggregates released by dying neurons trigger a proinflammatory M1 response, which in turn releases factors that promote further neuronal death and protein aggregation. The fact that proteins can be detected in the biological fluids of both healthy individuals and PD patients [61, 62] indicates that α-syn can elicit these damaging functions peripherally. The important role of microglial activation in PD has prompted scientists to define potential therapeutic candidates. Several regions of the human brain, including the striatum, hippocampus, midbrain, olfactory bulb, spinal cord, and cerebral cortex, express G protein-coupled receptor 40 (GPR40), a form of polyunsaturated fatty acid (PUFA) receptor [63]. GPR40 plays an anti-inflammatory, antioxidant and neuroprotective role, particularly when combined with PUFAs [64, 65]. The agonist TUG469 ameliorates neurodegeneration and motor impairment both in vitro and in animal models of PD by downregulating the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome [66]. In vitro, TUG469 reduced 6-OHDA (6-hydroxydopamine)-induced neurotoxicity, whereas in a 6-OHDA-induced mouse model of PD, TUG469 improved motor deficits, preserved both dopaminergic fibres in the striatum and SN and reduced microgliosis and astrogliosis [66]. In addition, in a mouse model of PD produced by injecting α-syn fibrils into the animal brain, TUG469 treatment reduced pSer129 syn levels and microgliosis and astrogliosis by modulating inflammasome activation, apoptosis and autophagy [66]. These observations support the notion that GPR40 activation may interfere with inflammatory responses, regulating NLRP3 expression, and this effect might contribute to a reduction in α-syn aggregation, thus limiting DA neuronal damage. Consequently, GPR40 has been identified as a potential therapeutic target for the treatment of PD [66]. A recent study describing extensive and heterogeneous microgliosis at the SN level in postmortem PD patients highlighted a positive correlation between the level of microgliosis and intracellular iron deposition [67]. In PD patients, plasma ferritin is moderately positively correlated with the levels of the inflammatory cytokine IL-6, hepcidin, the main regulator of iron homeostasis, and with L-DOPA levels [67]. The accumulation of free ferrous iron could contribute to the activation of ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation [68]. This mechanism is consistent with the observed oxidative stress and inflammatory responses in PD, further linking alterations in iron metabolism to neurodegeneration and potentially to disease progression. Notably, patients with elevated levels of inflammatory markers such as IL-6 exhibit a poor response to iron chelation [69]. This phenomenon may be attributed to the fact that once a chronic inflammatory milieu is established, iron becomes sequestered within the macrophages of the reticuloendothelial system and the brain’s microglia, rendering it inaccessible to chelation. Consequently, chelators may no longer effectively reach these intracellular iron pools. Furthermore, a significant clinical limitation associated with iron-chelating agents, including deferiprone, is the occurrence of neutropenia. Although this adverse effect is typically reversible upon treatment cessation, it remains a critical safety concern. Ongoing clinical trials involving patients with early-stage PD are currently evaluating the therapeutic efficacy and safety profile of chelation therapy to further define its clinical utility. Peripheral α-syn pathology The discovery of α-syn aggregates in peripheral tissues has shifted the view of PD as a multisystem disorder. This peripheral involvement has significant implications for our understanding of PD pathogenesis, early diagnosis, and potential therapeutic interventions. In the CNS, α-syn is expressed not only by neurons but also by microglia, astrocytes, and oligodendrocytes. Outside the brain, α-syn is present in various peripheral organs [70, 71] and tissues [72]. Furthermore, α-syn has always been considered exclusively intracellular, but it is now well known that it can be secreted by cells, probably through exosomes and membrane nanotube-mediated exocytosis. Both monomeric and oligomeric α-syn are detectable in the blood and CSF of healthy individuals and PD patients [61]. In PD patients, plasma α-syn levels are significantly higher than they are in healthy individuals, suggesting that circulating α-syn may serve as a predictor of motor-symptom severity [73]. Blood α-syn levels may reflect the abundance of intracellular α-syn in multiple cell types, including monocytes, hematopoietic precursor cells, erythrocytes, and platelets, all of which are elevated α-syn in PD [74, 75]. Potentially, changes in the level of intracellular α-syn could influence the function of blood cells, with a consequent possible impact on the brain immune status. However, few studies have examined how peripheral α-syn is related to CNS pathology. Notably, peripheral infusion of pathological α-syn into either the brain or the autonomic nervous system of rodents and nonhuman primates induces CNS α-syn pathology, supporting a transneuronal transmission mechanism [76–78]. In addition to accumulating in the bloodstream, α-syn aggregates also accumulate in the gastrointestinal tract of individuals with neurodegenerative diseases [79]. The enteric nervous system appears particularly vulnerable, and enteric α-syn pathology often precedes motor symptoms, supporting the hypothesis that PD may originate in the gut and propagate to the brain in a transsynaptic prion–like manner [80]. Among the proposed routes of spread, retrograde axonal transport through the vagus nerve is considered a key pathway driving α-syn propagation from the gut to the CNS [81, 82]. Furthermore, enteroendocrine cells may also contribute to the centripetal spread of misfolded α-syn [83]. In this respect, enteric α-syn accumulation could promote neurogenic immune/inflammatory responses, which impair intestinal barrier integrity and permeability and decrease tight junction protein expression [84, 85]. As permeability increases, α-syn, either free or within extracellular vesicles, can translocate into the systemic circulation along with microbial components. This systemic dissemination may enhance CNS infiltration and trigger innate immune activation, thereby contributing to neurodegeneration [85]. Consistent with the above findings, PD transgenic mice display an accumulation of enteric α-syn, alterations in the integrity and permeability of the intestinal barrier and a high degree of intestinal inflammation in the presymptomatic phases of the disease [85, 86]. PD patients also exhibit LB-like inclusions in enteric neurons of both the myenteric plexus and the submucosal plexus [87, 88], indicating that the gut-brain axis may play a key role in linking peripheral α-syn accumulation with CNS pathology [89]. A bidirectional communication system between the brain and gut has been well established, and α-syn-dependent microglial activation has been associated with alterations in the intestinal microbiota in both animal models and patients [90]. However, a direct and reciprocal relationship among α-syn accumulation, enteric inflammation, intestinal barrier impairment and PD onset has not yet been effectively established. Recent studies have documented the presence of LBs and α-syn deposits in multiple other peripheral locations, including the retina, olfactory epithelium, salivary glands, cardiac sympathetic nerves, adrenal glands, and skin [75, 91, 92]. Olfactory dysfunction is one of the earliest non-motor symptoms of PD, and its severity is correlated with cognitive decline and the risk of developing dementia [93]. α-Syn accumulation is found in the olfactory mucosa of PD patients, with positivity rates ranging from 46.3% to 69%, increasing when sampling is performed in the olfactory neuroepithelium rather than the middle turbinate area [94, 95]. The olfactory mucosa is directly connected to the CNS via olfactory nerve fibres, and α-syn deposition in the olfactory bulb correlates with α-syn accumulation in the amygdala [96]. Similarly, α-syn aggregates are detectable in the skin biopsies of PD patients, particularly in the cervical regions close to the autonomic nerves or lymph nodes [97–99]. This may reflect the high density of autonomic fibres in these areas and their proximity to brainstem regions strongly affected PD patients, which may increase the probability of detecting α-syn inclusions [100]. The above-reported evidence suggests that, on the basis of the initial localization of pathological forms of α-syn, different subtypes of PD can be identified in addition to the traditional staging framework based on the canonical Braak pattern, which is characterized by the caudo-rostral spread of α-syn-positive LBs, which originate in the brainstem and systematically ascends toward the neocortex [101, 102]. Recent neuropathological, imaging, and clinical evidence supports the concept of “body-first” and “brain-first” PD subtypes, which differ in the initial site and progression of α-syn pathology (Fig. 1) [82]. In “body-first” PD, misfolded α-syn aggregates may originate in peripheral tissues such as the enteric or autonomic nervous system and propagate centrally via the vagus nerve and sympathetic pathways; this subtype is often associated with prodromal autonomic dysfunction and rapid eye movement (REM) sleep behaviour disorder (RBD). In contrast, “brain-first” PD is characterized by initial central α-syn pathology, for example, in limbic structures or the olfactory bulb, with subsequent spread to peripheral sites. This model better accounts for cases that deviate from the canonical Braak pattern and underscores the multifactorial etiology of PD [82].Fig. 1Peripheral α-syn pathology: the “brain first” versus the “body first”. In the “brain-first” subtype, the disease originates in the brain, where it causes progressive, asymmetric neurodegeneration and late-onset autonomic dysfunction. In contrast, the “body-first” subtype of the disease begins in the enteric system, causing early, symmetric autonomic and brainstem dysfunction, and subsequently spreads to the rest of the brain Peripheral α-syn pathology: the “brain first” versus the “body first”. In the “brain-first” subtype, the disease originates in the brain, where it causes progressive, asymmetric neurodegeneration and late-onset autonomic dysfunction. In contrast, the “body-first” subtype of the disease begins in the enteric system, causing early, symmetric autonomic and brainstem dysfunction, and subsequently spreads to the rest of the brain Peripheral α-syn pathology, therefore, is a crucial aspect of PD pathogenesis, and the mechanisms underlying the spread of α-syn pathology from peripheral tissues to the brain remain unclear and represent an area of active research. Understanding the mechanisms of α-syn spread, as well as the impact of peripheral pathology on disease progression, is essential for the purpose of developing effective diagnostic and therapeutic strategies for PD. Further research is undoubtedly needed to fully elucidate the role of peripheral tissues in PD, with subsequent translation of these findings into clinical practice. Monocyte involvement in PD Monocytes are a key component of the peripheral innate immune system, and these cells perform multiple essential functions, including tissue infiltration and phagocytosis of pathogens and cellular debris. They also secrete cytokines and other bioactive molecules, present antigens to adaptive immune cells, and differentiate into dendritic cells and macrophages that acquire more specialized immune functions [23]. These cells are commonly classified into three main subsets -classical, intermediate, and nonclassical monocytes- each of which presents distinct, yet overlapping, functional profiles. Although PD is considered a neurodegenerative disorder, increasing evidence indicates that peripheral immune mechanisms play a significant role in its pathophysiology. Monocytic inflammation serves as a critical link between systemic immune responses and neurodegeneration, driving PD progression via several key mechanisms. Peripheral monocytes are capable of traversing the blood-brain barrier (BBB). This process is mediated by the upregulation of the C-C motif chemokine receptor 2 (CCR2), which is particularly prominent in advanced stages of PD, facilitating the recruitment of these cells to sites of neuroinflammation [103]. Furthermore, the infiltration of proinflammatory monocytes into the CNS exacerbates neuroinflammation, producing toxic effects on DA neurons within the SN. Indeed, blocking the recruitment of these cells into the CNS provides significant neuroprotection in preclinical PD models [28]. Considerable heterogeneity across studies suggests that monocyte activity may be influenced by a combination of intrinsic and extrinsic factors [23]. Changes in the subpopulation Analysis of the cellular distribution of peripheral blood cells revealed no significant differences in the proportions of classical (CD14+CD16−), intermediate (CD14+CD16+), and nonclassical (CD14−CD16+) monocyte subpopulations between PD patients and controls [23]. According to another report, the percentage of monocytes relative to total leukocytes was also comparable between PD patients and healthy controls [22]. Interestingly, within this overall similarity, PD patients displayed a shift in subset composition, with classical monocytes (CD16−) being enriched and CD16+ monocytes being reduced relative to healthy controls [22]. While the differences in frequencies were small or nonsignificant, previous studies have suggested that even minor shifts in monocyte populations can impact immune function, including cytokine production, phagocytic activity, and neuroinflammatory responses. For example, a modest increase in intermediate monocytes (CD14+ CD16+) has been associated with increased proinflammatory cytokine release, which could contribute to neurodegenerative processes even in the absence of statistically significant frequency changes [28]. Functional changes Phagocytosis Since monocytes and macrophages can enter the CNS in PD [28, 104], both cell types could be involved in the recognition of protein components and cellular debris [105, 106] and in the activation of phagocytotic mechanisms. These processes may subsequently drive an inflammatory response through cytokine generation and stimulation of the inflammasome. Changes in innate immune genes and cells in PD are suggested by the results of genetic, cellular and biomarker studies [107]. However, variations in peripheral immunity are often inconsistent, likely due to biological variability and differing study protocols [22, 108, 109]. Phagocytosis is reportedly impaired in peripheral PD monocytes, and this dysfunction is positively correlated with monocyte α-syn levels [22, 108]. Nevertheless, inconsistent evidence has been reported with respect to cytokine secretion in response to stimulation and phagocytosis [22, 109, 110]. This discrepancy is probably attributed to the different PD stages evaluated or the different methodological approaches employed. Indeed, assessments of functional phagocytic differences under conditions that more closely replicate the in vivo state (i.e., in media consisting of autologous PD sera) indicate increased, rather than reduced, bead–phagocytic capacity, contrasting with results obtained after prolonged incubation in artificial media [111]. Although additional studies are needed, these data support the presence of altered innate immune function in PD. Metabolism It is commonly accepted that immune cells undergo metabolic reprogramming to sustain dysfunction linked to neurodegeneration in PD [112, 113], whereby cellular metabolic alterations disrupt immune cell energy homeostasis, leading to aberrant inflammation in both the brain and the peripheral nervous system. These abnormalities are also evident in the PBMCs of individuals with PD. Monocytes display a phenotypic shift toward proinflammatory states. PD monocyte populations produce increased levels of IL-1β, IL-6, and TNF-α when subjected to inflammatory stimuli in vitro [23, 114]. Transcriptomic analyses further have revealed abnormal gene expression profiles in peripheral monocytes from PD patients [27, 115]. Metabolic features mirror these findings. Glycolytic activity, capacity, and reserve are greater in PBMCs from PD patients than in those from controls [116], and this feature is evident in PBMCs from patients affected by RBD, which is known to convert to PD or related synucleinopathies [117]. Since glycolysis inhibition can ameliorate inflammatory abnormalities associated with peripheral inflammation [118], targeting glycolysis might represent a conceivable strategy to mitigate aberrant inflammation in the prodromal stage of PD. Glucose dysmetabolism is also a prominent feature of Alzheimer disease [119]. Mitochondrial dysfunction has been demonstrated in many PD models, including human neurons and fibroblasts [120–123]. This phenomenon also appears to occur in PD PBMCs, where it is associated with increased levels of mitochondrial ROS and reduced levels of the antioxidant Cu-Zn superoxide dismutase [116]. The increased intracellular ROS production in PD PBMCs compared with matched controls does not occur at the expense of glutathione reductase [124] but is dependent on the daily levodopa dosage, suggesting that levodopa may help modulate the redox status of PBMCs [124]. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is the primary regulator of mitochondrial biogenesis and antioxidant defence systems and safeguards myeloid cells against inflammatory activation [125]. In PD monocytes, its levels are initially sustained but progressively decline as the disease burden increases [115]. Indeed, monocytic PGC-1α levels negatively correlate with increased motor impairment and patient disability [115]. Similarly, glutathione peroxidase 4 (GPX4), an essential mitochondrial antioxidant enzyme protecting cells from lipid peroxidation and ferroptosis [126], and nuclear factor erythroid 2-related factor 2 (NFE2L2), which governs the oxidative stress response and mitochondrial homeostasis [127, 128], initially increase but then markedly decrease in later disease stages [115]. Sirtuins 1 and 3 (SIRT1 and SIRT3), NAD+-dependent deacetylases vital for mitochondrial regulation and inflammation control [129, 130], also decrease during disease progression, with lower levels of SIRT3 even in early stages [115]. These changes suggest the progressive exhaustion of monocytic antioxidant defences, fostering a toxic microenvironment that promotes neurodegeneration. Failure of mitochondrial complexes of the respiratory chain is evident in PD PBMCs. Compared with that in controls, complex I activity is significantly lower in both idiopathic PD patients and PD patients carrying Parkin mutations, whereas complex IV activity is particularly decreased in idiopathic PD patients, indicating broader respiratory chain dysfunction [131]. These findings are consistent with increased mRNA levels of complexes I-V [132], which might suggest a compensatory mechanism for the reduced activity. With respect to respiration parameters measured in PD PBMCs, inconsistent results have been obtained. The increased maximal and spare respiratory capacity in PD PBMCs compared with neurologically healthy controls (NHCs) [133] was not confirmed in other studies [116]. This may be ascribed to the presence of different subsets of PBMCs that are differently affected by respiratory dysfunction. However, the mitochondrial membrane potential (MMP) in PD PBMCs was found to be significantly altered compared with that in healthy PBMCs [116, 134], suggesting that its evaluation in PBMCs may serve as an early marker of apoptosis in PD. The accumulation of α-syn aggregates within neurons, leading to the formation of LBs, has recently been linked to impaired lysosomal function [135, 136]. This association is further supported by the identification of mutations in the leucine-rich repeat kinase 2 (LRRK2) and glucosylceramidase beta 1 (GBA1) genes in familial PD. LRRK2 and GBA1 encode proteins that regulate lysosomal function [137, 138], and both are relevant for immune cell function [139]. Lysosomes and autophagy are the main regulators of inflammation through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling and inflammasome activation [140]. The role of LRRK2 in immune cells is currently being investigated. The most common pathogenic mutation in LRRK2 involves the substitution of glycine (G) with serine (S) at position 2019 (G2019S), which is located within the highly conserved DFG (Asp-Phe-Gly) motif immediately preceding the activation loop of the LRRK2 kinase domain. The discovery that the G2019S mutation results in a constitutive two- to threefold increase in LRRK2 kinase activity [141, 142], along with evidence that LRRK2 mutations are risk factors for the more common sporadic form of PD [143, 144], prompted extensive investigation into its functional role. Compared with healthy controls, PD monocytes display higher LRRK2 levels. The highest expression of LRRK2 is present in the CD14+/CD16+ population [145]. LRRK2 is readily detectable in the immortalized mouse RAW264.7 macrophage cell line as well as in primary mouse bone marrow-derived macrophages (BMDMs) [146]. LRRK2 occurs when human PBMCs are treated with interferon gamma (IFN-γ) [145, 147]. Additionally, both the mRNA and protein expression of LRRK2 reportedly increase following treatment of PBMCs with interferon beta (IFN-β) and TNF-α [147]. Conflicting results concerning the LRRK2 response to LPS have been reported, possibly due to inconsistencies among the LRRK2 antibodies used, the concentration of LPS and the time points investigated [146, 148, 149]. This factor complicates the determination of whether the protein drives or inhibits inflammatory processes (Table 1). In various microglial models, LRRK2 appears to drive inflammatory processes; indeed, its inhibition has been shown to attenuate cytokine release [150, 156]. However, LRRK2 is essential for preventing excessive inflammation relevant to Crohn’s disease, as it negatively regulates the nuclear factor of activated T cells (NFAT) pathway in macrophages [149]. In the same cell type, LRRK2 knockdown does not significantly impact TLR-mediated cytokine production [151]. These discrepancies suggest that LRRK2 regulates inflammation through cell type-specific mechanisms or that compensatory pathways may be at play within different immune populations. With respect to cell motility, contradictory findings have emerged concerning the role of the G2019S mutation. Some evidence suggests that this mutation enhances the recruitment of myeloid cells to inflammatory sites [153]; conversely, other studies suggest that it impairs microglial motility [154], potentially hindering the ability of cells to respond effectively to injury. For these reasons, while inhibiting LRRK2 kinase activity is considered a promising neuroprotective strategy in PD, primarily by reducing α-syn-mediated inflammation, there are concerns regarding “off-target” systemic effects. Excessive suppression of LRRK2 function could trigger inflammatory responses or compromise the ability of the immune system to clear pathogens [155].Table 1Conflicting role of LRRK2 in inflammationContextResultLRRK2 possible roleReferencesTLR4 activation (Microglia)LRRK2 inhibition or knockdown attenuates the secretion of proinflammatory cytokines such as IL-1β, IL-6, and TNF-αProinflammatory[150]Dectin-1 Pathway (Macrophage)LRRK2 knockdown increases cytokine production through NFAT nuclear translocation.Negative regulator of inflammation[149, 151]Pathogen responseImmune activation triggers LRRK2 upregulationPromotes recruitment to autophagosomes, for effective bacterial degradation[152]Motility (G2019S)The G2019S mutation increases macrophage motilityIncreases recruitment following brain damage[153]Motility (G2019S)The G2019S mutation attenuates microglial motilityImpairs effective response to brain damage[154]Parkinson vs Crohn diseaseGain of function in PD/Loss of function in Crohn’s disease.Context-dependent effects: the loss of LRRK2 compromises intestinal health[155] Table 1Conflicting role of LRRK2 in inflammationContextResultLRRK2 possible roleReferencesTLR4 activation (Microglia)LRRK2 inhibition or knockdown attenuates the secretion of proinflammatory cytokines such as IL-1β, IL-6, and TNF-αProinflammatory[150]Dectin-1 Pathway (Macrophage)LRRK2 knockdown increases cytokine production through NFAT nuclear translocation.Negative regulator of inflammation[149, 151]Pathogen responseImmune activation triggers LRRK2 upregulationPromotes recruitment to autophagosomes, for effective bacterial degradation[152]Motility (G2019S)The G2019S mutation increases macrophage motilityIncreases recruitment following brain damage[153]Motility (G2019S)The G2019S mutation attenuates microglial motilityImpairs effective response to brain damage[154]Parkinson vs Crohn diseaseGain of function in PD/Loss of function in Crohn’s disease.Context-dependent effects: the loss of LRRK2 compromises intestinal health[155] Conflicting role of LRRK2 in inflammation The GBA1 gene encodes the lysosomal enzyme glucocerebrosidase (GCase), which represents a major genetic risk factor for PD [157, 158]. Research has recently linked GCase activity to the clearance of α-syn aggregates [135]. GCase activity is correlated with increased neuroinflammation, α-syn aggregation, and neurodegeneration [159–161]. In PD monocytes, GCase activity is reduced relative to controls [162]. The inactivating mutation of GBA1 results in autophagic defects and increased release of IL-1β and IL-6 [163], which is consistent with the role of GBA1 in controlling aberrant inflammation. In line with this finding, the pharmacologic GCase activator NCGC758 [163] reverses inflammatory alterations, indicating that the rescue of GCase activity could have therapeutic benefits in preventing aberrant inflammation. In summary, the reported evidence on monocytic abnormalities in PD patients often appears contradictory, probably due to possible confounding elements that need to be carefully considered in monocyte-related studies. In the early stages of PD, monocytes exhibit an upregulation of transcripts associated with an M2 phenotype. However, this increase appears to be transient, as these markers decline sharply in advanced stages of the disease. This finding suggests that monocytes initially mount a compensatory response to counteract neuroinflammation, which ultimately fails as the pathology worsens. Antioxidant stress response pathways fluctuate depending on the disease stage, indicating early adaptation to oxidative stress followed by exhaustion of monocytic antioxidant defences. Another potential confounding factor arises from dopaminergic therapy. Given that dopamine can modulate monocytic activation and chemotaxis, it remains challenging to distinguish whether the observed abnormalities are intrinsic to PD or secondary to pharmacological intervention. Additionally, discrepancies exist between systemic soluble protein levels and intracellular gene expression, indicating a complex dynamic localization of specific markers. Finally, biological sex contributes significantly to heterogeneity. The robust correlations between inflammatory monocytic transcripts and disease severity in females are not evident in males, suggesting that sex profoundly influences monocytic response patterns. This dimorphism complicates the use of these cells as universal biomarkers. Peripheral-central neuroimmune cross talk The status of barrier protection in PD The BBB, the blood-cerebrospinal fluid barrier (BCSFB) and the meninges are critical gatekeepers that regulate the passage of substances between the systemic circulation and the CNS. The BBB system is essential for understanding the pathogenesis of neurodegenerative disorders, including PD. The protection of the internal environment of the CNS from the external environment occurs at three points within three different defensive barriers. In this respect, the BBB, BCSFB and meningeal barrier, especially the arachnoid barrier, are the three protective mechanisms [164, 165]. The primary anatomical unit of the vascular BBB is represented by brain endothelial cells, which have peculiar properties that can limit the free diffusion of molecules from the blood to the brain barrier. They are also involved in the regulation of the passage of hormones, peptides, proteins and nutrients. Furthermore, the BBB is an important signalling and secretory interface capable of regulating immune surveillance in the brain [166]. The barrier functions of the BBB are conferred by the expression of specialized tight junction proteins, high levels of efflux transporter expression and low rates of pinocytosis in endothelial cells. Tight junction protein complexes localize to cell‒cell junctions, where they limit the diffusion of substances between cells. Tight junctions consist of integral membrane proteins, including claudin-5 and Occludin, and junctional adhesion molecules, such as zonula occludens [165]. In contrast, the BCSFB is a structure present at the level of the cerebral epithelial cells that make up the choroid plexus, which is in each of the four cerebral ventricles. In this context, the arachnoid epithelial cells also contribute to the formation of the BCSFB. Furthermore, the endothelial cells that make up the vasculature in the choroid plexus do not allow the leakage of serum components into the stroma of the choroid plexus, which makes the latter a less selective barrier than the BBB [167]. In this regard, the vascularization of the choroid plexus also allows the trafficking of leukocytes. For this reason, the stroma within the choroid plexus is a site of active immune surveillance. The epithelial cells of the choroid plexus belonging to the BCSFB are similar to those of the BBB. Indeed, they express specialized tight junction proteins and efflux transporters that contribute to the selective properties of the barrier. However, in this barrier, endothelial cells express different tight junction proteins, such as claudin 1, claudin 2, and claudin 11 [168]. Moreover, the epithelium of the choroid plexus is the main site of CSF production, and the transporters present at the level of the endothelial cells are important for regulating the composition of the CSF [169]. Furthermore, although the arachnoid epithelium is not a site for CSF production, it expresses claudin 11 together with efflux transporters such as P-glycoprotein, which can influence the penetration of any pharmacological molecules into the brain [166]. The brain parenchyma, under physiological conditions, contains very low levels of blood-derived leukocytes, whereas the CSF and meninges contain resident populations of blood-derived leukocytes that are able to enter these compartments. Thus, both the choroid plexus and the arachnoid epithelial cells of the BCSFB appear to be the major routes through which leukocytes enter the CSF under normal conditions but, importantly, may also be a route of entry in injured states [170, 171]. BBB dysfunction plays a significant role in the pathogenesis of PD. In fact, damage to the BBB allows immune cells and plasma proteins to enter the brain parenchyma where the neuroinflammatory mechanisms are initiated. This neuroinflammation, triggered by activated glial cells, consequently contributes to neurotoxicity and therefore to neuronal dysfunction [165]. BBB impairment, including reduced expression or weakening of tight junctions, is responsible for the disruption of BBB integrity in PD, leading to increased vascular permeability and the accumulation of LBs, proteins and other intermediates, such as oligomeric α-syn in neuronal cells, the basal ganglia and activated astrocytes from the SNpc [172, 173]. BBB disruption is induced by LPS, which causes a reduction in tight junction protein expression and consequently neuroinflammation. Neuroinflammation itself contributes to BBB breakdown, amplifying the overall pathophysiology of PD [165]. Inflammatory mediators released by perivascular cells such as microglia and astrocytes can cause BBB injury by increasing neuroinflammation. Furthermore, infiltrating immune cells derived from the circulation, including neutrophils and T lymphocytes, can, in turn, increase BBB permeability by amplifying neuroinflammation, which may contribute to the pathogenesis of PD [174]. With respect to the meningeal barrier, few studies have investigated dynamic meningeal activity during PD development and the functionality of meningeal lymphatic vessels. Blocking meningeal lymphatic drainage in A53T mice overexpressing mutant human α-syn induced a severe PD-like phenotype, marked by α-syn accumulation, neuroinflammation, dopaminergic neuron loss, motor deficits, T-cell accumulation in the meninges, and a reduction in deep cervical lymph nodes [175]. Injection of preformed α-syn fibrils in mice induced pathological changes, leading to impaired meningeal lymphatic drainage, loss of endothelial tight junctions, and increased meningeal inflammation [176]. To our knowledge, however, no study has specifically explored how meningeal T cells contribute to the pathogenesis of PD. As noted above, evidence of BBB breakdown in PD includes serum protein leakage into the brain parenchyma and infiltration of peripheral immune cells, which may promote neuroinflammation and neuronal damage. Alterations in the BCSFB and meningeal barrier may further impair the clearance of toxic metabolites, facilitating the CNS spread of pathological α-syn aggregates. Murine models of PD corroborate these findings, showing increased BBB and meningeal permeability and altered expression of tight junction proteins critical for barrier integrity. These observations highlight the need to better understand barrier dysfunction in PD and its potential as a therapeutic target [177–180]. Peripheral inflammatory markers in PD Cytokines and chemokines Building on the evidence discussed in the previous sections, increased peripheral levels of proinflammatory cytokines and chemokines have emerged as a key feature of PD, reflecting systemic inflammatory dysregulation. As reported by Reale et al. (2009) [20], isolated PBMCs from patients were stimulated with LPS as a tool to probe underlying immune dysregulation, and elevated cytokine levels were quantified. Specifically, significantly elevated levels of proinflammatory cytokines, including TNF-α, IL-1β, and IFN-γ; C-C motif chemokines 2, 3, and 5 (CCL2, CCL3, and CCL5); and interleukin-8 (IL-8), respectively, were detected in cells from PD patients both at baseline and, in particular, following LPS stimulation. The levels of some of these cytokines correlated with disease severity, as measured by the Unified PD Rating Scale motor score (UPDRS) and Hoehn and Yahr stages, suggesting their potential as biomarkers of disease progression and severity. Importantly, while individual studies have reported variable cytokine profiles, these apparently conflicting findings likely reflect differences in disease stage, biological compartment analysed, treatment status, and patient stratification rather than true inconsistencies across studies [181]. The heightened cytokine response to LPS reflects a primed immune state in PD, potentially driven by factors such as increased TLR4 expression, preactivated inflammatory pathways, epigenetic modifications and NF-κB activation [20]. Given the pleiotropic effects of these cytokines and chemokines, the inflammatory response likely has a broader systemic scope, involving different cellular populations, including both immune and brain-resident cells. Accordingly, the following sections summarize and discuss evidence derived from both PD patients and experimental animal models, providing an integrated overview of the contributions of specific cytokines and chemokines to PD pathophysiology (Table 2).Table 2Summary of peripheral cytokines and chemokines associated with PDExpression in PDRole in PDAssociation with PD treatment, severity and progressionTNF-αElevated in brain, CSF, serum [15, 182]Central proinflammatory cytokine; drives microglial and astrocytic activation, oxidative stress, excitotoxicity, BBB disruption and α-syn-NF-κB signalling [183, 184]Strongly associated with motor severity (MDS-UPDRS III), Hoehn-Yahr stage [185], nonmotor symptoms, grey matter atrophy [185–187] and mortality risk [188]; TNF-α polymorphisms associated with PD susceptibility [177, 189]; anti-TNF-α therapies indirectly associated with reduced PD risk [190]IL-1βElevated in brain, CSF [184]Proinflammatory; promotes microglial activation and dopaminergic neuron loss [184]; excitotoxicity [183, 184] and IL-6 production [191–193]; confer neuroprotection under specific conditions [194]Higher levels associated with motor and nonmotor symptom severity [186]; IL1B polymorphisms linked to increased PD risk and earlier onset [184, 189, 195]IFN-γElevated in nigrostriatal regions [196–198]Proinflammatory; promotes M1 microglial polarization via JAK/STAT [186, 198]; synergizes with TNF-α and IL-1β [186, 198]; modulates adaptive immunity with possible neuroprotective effects [186]UnclearIL-2Elevated in brain, CSF, serum [20, 187]Proinflammatory; drives T-cell proliferation and expansion of IFN-γ-producing T cells [187, 199, 200]Treatment with anti-parkinsonian drugs appears to reduce IL-2 serum levels [20, 200]IL-6Elevated in CSF, serum [187, 192, 193]Proinflammatory; modulates acute-phase response, BBB integrity and lymphocyte recruitment [20, 192]; mixed pro- and neuroprotective effects [187]Correlates with disease severity, progression and tremor-dominant phenotypes [187, 192, 193]IL-8Variable; unchanged or decreased [183, 201]Proinflammatory; neutrophil recruitment; autocrine microglial signalling [201]Weak correlation with motor severity (UPDRS III) [20]CCL2Elevated in serum, CSF [185]Proinflammatory; mediates CCR2+ monocyte recruitment across the BBB; amplifies α-syn-driven inflammation [28]Reduced plasma levels in PD patients carrying GBA mutations [202]CCL3Elevated in CSF of patients with severe motor symptoms [20, 203]Proinflammatory; promotes leukocyte recruitment via CCR5 [204]Preferentially associated with advanced disease and severe motor phenotypes [203]; promising blood-based biomarker for motor severity stratification [203]CCL5Increased in serum of patient with severe disease [205]Proinflammatory; facilitates Th17 infiltration into the SN, contributing to dopaminergic loss [206]Potential biomarker; requires further validation [205]TGF-β1Elevated in striatum, CSF [207, 208]Anti-inflammatory and neuroprotective at physiological levels [209, 210]; detrimental when overactivated [207, 209]UnclearIL-4Variable, slight decrease [187, 199, 211]Dual role: neuroprotective or proinflammatory depending on context [187, 211]UnclearIL-10Elevated in serum [193]Anti-inflammatory and neuroprotective; inhibits microglial activation and oxidative stress [212, 213]IL10 promoter polymorphisms associated with early-onset PD [214]; increased levels linked to motor-predominant PD, promising therapeutic target [215–217]IL-13Not directly measuredNeuroimmune modulator; Modulates neuronal susceptibility to oxidative stress via IL-13RA1 [211]IL13 and IL13RA1 polymorphisms associated with increased PD risk and oxidative stress [218] Table 2Summary of peripheral cytokines and chemokines associated with PDExpression in PDRole in PDAssociation with PD treatment, severity and progressionTNF-αElevated in brain, CSF, serum [15, 182]Central proinflammatory cytokine; drives microglial and astrocytic activation, oxidative stress, excitotoxicity, BBB disruption and α-syn-NF-κB signalling [183, 184]Strongly associated with motor severity (MDS-UPDRS III), Hoehn-Yahr stage [185], nonmotor symptoms, grey matter atrophy [185–187] and mortality risk [188]; TNF-α polymorphisms associated with PD susceptibility [177, 189]; anti-TNF-α therapies indirectly associated with reduced PD risk [190]IL-1βElevated in brain, CSF [184]Proinflammatory; promotes microglial activation and dopaminergic neuron loss [184]; excitotoxicity [183, 184] and IL-6 production [191–193]; confer neuroprotection under specific conditions [194]Higher levels associated with motor and nonmotor symptom severity [186]; IL1B polymorphisms linked to increased PD risk and earlier onset [184, 189, 195]IFN-γElevated in nigrostriatal regions [196–198]Proinflammatory; promotes M1 microglial polarization via JAK/STAT [186, 198]; synergizes with TNF-α and IL-1β [186, 198]; modulates adaptive immunity with possible neuroprotective effects [186]UnclearIL-2Elevated in brain, CSF, serum [20, 187]Proinflammatory; drives T-cell proliferation and expansion of IFN-γ-producing T cells [187, 199, 200]Treatment with anti-parkinsonian drugs appears to reduce IL-2 serum levels [20, 200]IL-6Elevated in CSF, serum [187, 192, 193]Proinflammatory; modulates acute-phase response, BBB integrity and lymphocyte recruitment [20, 192]; mixed pro- and neuroprotective effects [187]Correlates with disease severity, progression and tremor-dominant phenotypes [187, 192, 193]IL-8Variable; unchanged or decreased [183, 201]Proinflammatory; neutrophil recruitment; autocrine microglial signalling [201]Weak correlation with motor severity (UPDRS III) [20]CCL2Elevated in serum, CSF [185]Proinflammatory; mediates CCR2+ monocyte recruitment across the BBB; amplifies α-syn-driven inflammation [28]Reduced plasma levels in PD patients carrying GBA mutations [202]CCL3Elevated in CSF of patients with severe motor symptoms [20, 203]Proinflammatory; promotes leukocyte recruitment via CCR5 [204]Preferentially associated with advanced disease and severe motor phenotypes [203]; promising blood-based biomarker for motor severity stratification [203]CCL5Increased in serum of patient with severe disease [205]Proinflammatory; facilitates Th17 infiltration into the SN, contributing to dopaminergic loss [206]Potential biomarker; requires further validation [205]TGF-β1Elevated in striatum, CSF [207, 208]Anti-inflammatory and neuroprotective at physiological levels [209, 210]; detrimental when overactivated [207, 209]UnclearIL-4Variable, slight decrease [187, 199, 211]Dual role: neuroprotective or proinflammatory depending on context [187, 211]UnclearIL-10Elevated in serum [193]Anti-inflammatory and neuroprotective; inhibits microglial activation and oxidative stress [212, 213]IL10 promoter polymorphisms associated with early-onset PD [214]; increased levels linked to motor-predominant PD, promising therapeutic target [215–217]IL-13Not directly measuredNeuroimmune modulator; Modulates neuronal susceptibility to oxidative stress via IL-13RA1 [211]IL13 and IL13RA1 polymorphisms associated with increased PD risk and oxidative stress [218] Summary of peripheral cytokines and chemokines associated with PD Tumor necrosis factor TNF-α is a pivotal proinflammatory cytokine implicated in the pathogenesis and progression of PD. Elevated levels of TNF-α have been observed in the serum, CSF and brain of PD patients, with TNF-α being detected in DA neurons, supporting a direct link between peripheral inflammation and neuronal vulnerability [15, 182]. This cytokine, which is produced primarily by activated microglia and astrocytes, exerts neurotoxic effects, promoting neuroinflammation, excitotoxicity, and BBB disruption [183, 184]. In addition to its direct effects, TNF-α acts within a cytokine network that shapes neuroinflammatory responses in PD. TNF-α and IL-1β mutually induce each other in the periphery; this reciprocal amplification is more restricted within the brain parenchyma, indicating tighter regulation of cytokine interactions in the CNS [184]. In the brain, TNF-α acts synergistically with IFN-γ to sustain microglial and astrocytic activation [182], promoting the induction of pro-oxidant enzymes, such as iNOS and NADPH oxidase, that contribute to oxidative stress and dopaminergic neurodegeneration [189]. Moreover, TNF-α, together with IL-1β, represents a major upstream stimulus for neuronal and glial IL-6 production [191–193]. Consistently, elevated circulating IL-6 levels are associated with increased mortality risk and greater motor symptom severity in PD, reflecting a sustained TNF-α-driven inflammatory state [188]. Motor symptom severity, as assessed by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS III), is directly associated with TNF-α levels, with higher scores corresponding to increased serum cytokine concentrations [185]. Additionally, the interaction of TRAF6 (TNF-α receptor-associated factor 6) with wild-type α-syn promotes NF-κB activation and TNF-α upregulation, exacerbating neuronal vulnerability and linking TNF-α signalling to α-syn-driven inflammatory cascades [161, 166]. TNF-α levels are significantly associated with clinical disease severity, as patients in advanced Hoehn-Yahr stages present higher cytokine concentrations than those in early-stage disease [185]. TNF-α has also been associated with both nonmotor symptoms and region-specific grey matter atrophy, linking systemic inflammation to structural brain changes [185–187]. Genetic studies have established a significant association between TNF-α polymorphisms and PD susceptibility [177, 189]. Microglial activation, a hallmark of PD, further amplifies TNF-α expression, suggesting a feed-forward inflammatory loop in which TNF-α acts both as an effector and a propagator of microglial reactivity [153, 161]. Furthermore, anti-TNF-α-treated inflammatory bowel disease (IBD) patients display a reduced PD risk compared with the untreated IBD patients, providing indirect evidence that long-term TNF-α suppression may mitigate PD development [190]. However, TNF-α has a concentration-dependent effect and exerts neuroprotective effects at physiological levels through facilitating synaptic plasticity and myelination, suggesting that dysregulated rather than basal TNF-α signalling is pathogenic [184]. Despite these findings, inconsistencies remain in experimental models regarding the role of TNF-α in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration [184, 189, 219]. The administration of MPTP to Tnf knockout mice resulted in a decrease in DA content in the striatum [184]. However, mice do not maintain elevated cytokine levels in their blood 24 hours after MPTP treatment, suggesting that acute toxin models may incompletely recapitulate the chronic TNF-α-driven inflammation observed in PD [182]. Studies on Tnf knockout mice or mice lacking TNF-α receptors have produced mixed results, probably because other mechanisms compensate for the loss of TNF, since blocking only one cytokine may not be sufficient to prevent DA neuronal death caused by inflammation. This finding highlights the redundancy and network-based nature of inflammatory signalling [189]. Interleukin-1 beta IL-1β is a central mediator of neuroinflammation, which is implicated in PD pathogenesis. Increased levels of IL-1β have been observed in PD brains and CSF, promoting DA neuron degeneration via microglial activation and reinforcing local inflammatory signalling within vulnerable nigrostriatal regions [184]. Chronic IL-1β expression within the SNpc results in microgliosis, inflammatory infiltration, and progressive neuronal loss [184]. Experimental studies in animal models indicate that IL-1β acts upstream of other proinflammatory cytokines, as the administration of an IL-1β receptor antagonist not only attenuates neurodegeneration but also significantly reduces TNF-α and IFN-γ protein levels in the mesencephalon [195]. A strong positive correlation has been observed between IL-1β and IL-6 levels; indeed, IL-1β acts as a potent inducer of neuronal IL-6 synthesis, thereby amplifying the inflammatory cascade [193]. Moreover, IL-1β priming sensitizes neurons to excitotoxic damage, and the NLRP3 inflammasome-driven activation of IL-1β is increasingly recognized in PD progression [184, 220]. As observed for TNF-α, higher IL-1β levels are associated with both motor and nonmotor symptom severity [186]. Genetic studies have revealed that IL1B polymorphisms are associated with increased PD risk, suggesting that individual variability in both TNF-α and IL-1β may influence disease susceptibility and early onset [184, 189, 195]. Nevertheless, IL-1β may also confer neuroprotection under specific conditions [184]. The dual roles of IL-1β in PD appear to reflect differences in signalling intensity and persistence, whereby chronic elevation is associated with neurodegenerative outcomes, whereas transient or low-level activation may be compatible with homeostatic or protective immune functions. Such conditions may lead to the release of neurotrophic factors or the clearance of toxic debris, ultimately promoting neuronal survival [194]. Interferon gamma IFN-γ is a proinflammatory cytokine with a complex role in PD. Elevated levels of IFN-γ in PD patients have been detected in nigrostriatal dopaminergic regions, including the SNpc and putamen [196–198]. This regional enrichment suggests spatial coupling between IFN-γ signalling and vulnerable dopaminergic populations. The activation of the JAK/STAT signalling cascade by IFN-γ drives microglia toward a proinflammatory M1 state, thereby accelerating neuronal damage, particularly in inflammatory environments enriched with cytokines such as TNF-α and IL-1β [186, 198]. Interestingly, IFN-γ may exhibit both neurotoxic and neuroprotective effects depending on context, likely reflecting differences in disease stage and immune milieu. Moreover, IFN-γ can exacerbate dopaminergic neuron loss through synergistic action with TNF-α [182, 186], while also possibly delaying neurodegeneration by modulating Th17 differentiation and NK cell activity. This suggests a role for IFN-γ in shaping adaptive immune responses during later or compensatory phases of PD [186]. Some studies have shown that PD patients have a Th1-skewed immune response with elevated IFN-γ/IL-4 ratios, which implies a dominance of cell-mediated immunity and proinflammatory responses, in line with the neuroinflammatory processes observed in PD [187, 199]. Interleukin-2 Interleukin-2 (IL-2) plays an important role in immune regulation and has been implicated in PD pathogenesis, as elevated IL-2 levels have been observed in the brain, CSF, and serum of PD patients [20, 187]. IL-2 promotes T-cell proliferation and may contribute to the T-cell imbalance observed in PD, which is characterized by an increase in IFN-γ-producing T cells [187, 199, 200]. Treatment with antiparkinsonian drugs appears to reduce IL-2 serum levels, linking its expression to disease activity and suggesting its involvement in the peripheral immune dysregulation associated with the disease [20, 200]. Interleukin-6 IL-6 is a cytokine with both proinflammatory and neuroprotective functions in PD. Elevated IL-6 levels have been reported in the serum and CSF of PD patients and are correlated with disease severity and progression, with evidence suggesting an association with tremor-dominant clinical phenotypes [187, 192, 193]. IL-6 facilitates PD by modulating acute-phase responses, lymphocyte recruitment, and BBB integrity, influencing both peripheral immune activation and CNS accessibility [20, 192]. In animal models, IL-6 deficiency exacerbates dopaminergic depletion, suggesting a neuroprotective role under certain circumstances [187]. However, findings on the relationship of IL-6 with PD symptoms and L-DOPA treatment, which restores movement control close to normal, remain inconclusive [193]. The evidence underscores the complex, context-dependent effects of IL-6, making it a potential, although still controversial, biomarker and therapeutic target, particularly with respect to the inflammatory motor subtypes of PD [187, 188, 192]. Interleukin-8 IL-8 is a proinflammatory chemokine, and conflicting evidence on its involvement in PD has been reported. Some studies report no difference in IL-8 levels between PD patients and controls, whereas others indicate a decreased IL-8 level in PD patients [183, 201]. IL-8 mediates neutrophil recruitment and interacts with microglia through autocrine signalling [201]. A weak correlation with motor symptom severity (UPDRS III score) has been suggested [20], which could reflect systemic inflammatory activity associated with disease rather than a causal role in neurodegeneration. C-C motif chemokine 2 CCL2 (also known as MCP1) is a chemokine that promotes monocyte recruitment and neuroinflammation. Within the inflammatory framework of PD, CCL2 appears to function primarily as a mediator of peripheral immune cell trafficking rather than as a direct driver of dopaminergic neurodegeneration. Some studies have reported increased CCL2 levels in the serum and CSF of PD patients, although associations with disease severity remain unclear [185]. Reduced plasma CCL2 levels have been described in PD patients carrying GBA mutations, suggesting that genetic background may influence CCL2 regulation [202]. CCL2 recognizes CCR2 receptors on myeloid cells, promoting their migration across the BBB, where they differentiate into inflammatory macrophages and dendritic cells [28]. The overexpression of α-syn promotes CCR2+ monocyte infiltration into the CNS, exacerbating inflammation and neurodegeneration and placing CCL2-mediated recruitment within broader α-syn-driven inflammatory cascades rather than isolated chemokine signalling [28]. Overall, the available evidence does not indicate a consistent association between peripheral CCL2 levels and PD diagnosis or clinical phenotypes. Similar to other cytokines and chemokines, methodological constraints and confounding factors affecting peripheral immune markers limit the interpretation of the findings [185]. C-C motif chemokine 3 C-C motif chemokine 3 (CCL3, also known as MIP-1α) is a proinflammatory chemokine that is elevated in PD patients with severe motor symptoms [20, 203]. Relative to the spectrum of chemokine alterations in PD, CCL3 appears to be preferentially associated with advanced or more severe disease phenotypes rather than early pathogenic stages. CCL3 promotes leukocyte recruitment via CCR5 signalling, which has been shown to inhibit long-term potentiation due to an attenuation of MAPK/CREB signalling and diminished hippocampal synaptic transmission, thereby contributing to cognitive impairment and neurodegeneration [204]. CCL3 may also serve as a blood-based biomarker to stratify PD motor severity [203]. C-C motif chemokine 5 C-C motif chemokine 5 (CCL5, also known as RANTES) is another chemokine associated with immune dysregulation in PD. PBMCs from PD patients produce more CCL5, especially upon stimulation with LPS [20]. Higher serum CCL5 levels have also been correlated with disease severity [205]. CCL5 may promote the infiltration of Th17 cells into the SN, contributing to dopaminergic cell loss in experimental models, thereby linking peripheral immune activation to CNS-directed inflammatory damage [206]. Despite its potential significance, some studies have not identified statistically significant differences between PD patients and controls [20], suggesting the need for further validation. Transforming growth factor beta-1 TGF-β1 has a context-dependent role in PD. Elevated levels of TGF-β1 have been detected in the striatum and CSF of PD patients [207, 208]. TGF-β1 has a neuroprotective effect by inhibiting microglial activation via inflammatory signals, such as IFN-γ and MPP+ toxicity [209, 210]. However, excessive TGF-β1 signalling can worsen dopaminergic deficits in MPTP models, underscoring the context-dependent role of TGF-β1 in PD [207, 209]. Interleukin-4 IL-4 is an anti-inflammatory cytokine that plays a dual role in PD. While some studies in PD models have revealed neuroprotective functions related to dopaminergic neuron survival, others have suggested a proinflammatory effect in LPS-treated models in which IL-4 exacerbates microglial activation and BBB disruption [187, 211]. IL-4 levels are variably reported in PD patients, with some studies indicating no significant differences compared with controls, while others reporting that the population of IL-4-producing cells is significantly lower in PD patients than in controls [187, 199, 211]. Therefore, these divergent findings highlight the complex functions of IL-4 in neuroinflammatory environments. Interleukin-10 IL-10 is an anti-inflammatory pleiotropic cytokine that has been suggested to be involved in neuroprotective mechanisms in PD. The elevated serum levels of IL-10 observed in PD patients compared with healthy controls may represent a compensatory anti-inflammatory response to ongoing neuroinflammation rather than a direct marker of neuroprotection, particularly in the presence of concomitant increases in proinflammatory cytokines [193]. IL-10 protects DA neurons from degeneration by inhibiting microglial activation and superoxide production via JAK1 signalling, thereby limiting oxidative stress-mediated neuronal damage [212, 213]. This effect has also been observed in animal models in which IL-10 administration reduced dopaminergic cell loss and neuroinflammation [194, 212, 221]. Genetic studies also suggest associations between IL-10 promoter polymorphisms and early-onset PD in a specific population [214]. Although plasma IL-10 levels are increased in PD patients with predominant motor symptoms, their lack of association with nonmotor manifestations suggests a context-dependent role, with currently limited but promising evidence supporting the therapeutic potential of IL-10-based strategies in PD [215–217]. Interleukin-13 IL-13 is a modulator of dopaminergic neuron survival through its receptor IL13RA1, which is expressed in the SNpc and ventral tegmental area of the brain [211]. Considering the inflammatory framework of PD, IL-13 appears to act as a susceptibility-modifying factor rather than as a classical inflammatory mediator. Although direct measurements of IL-13 levels in PD patients are lacking, genetic studies have linked IL13 and IL13RA1 polymorphisms to increased oxidative stress and elevated PD risk [218], as has been reported for the other cytokines mentioned above. IL-13 increases the sensitivity of cells to oxidative damage via IL13RA1, and inflammatory models of PD in mice lacking this receptor are partly protected [211]. Inflammasome The inflammasome is a multi-protein intracellular complex increasingly recognized as a crucial factor in neuroinflammation and neurodegeneration. Its activation accelerates the development of several age-related disorders, such as PD [222]. The inflammasome governs the innate inflammatory response within immune cells. Furthermore, it acts as a primary orchestrator in the relay of inflammation from the periphery to the CNS [223]. Generally, inflammasomes consist of a NLR inflammatory monomer, an effector protein (procaspase-1), and an adapter protein (apoptosis-associated speck-like protein, ASC) [224]. Activation leads to assembly of the inflammasome complex in peripheral and brain immune cells. This, in turn, promotes the autoproteolytic activation of caspase-1, leading to the secretion of proinflammatory cytokines and the cleavage of gasdermin D, thereby inducing pyroptosis [225]. Inflammasome activation can also be caused by various factors, such as α-syn aggregation, mitochondrial dysfunction, and reactive oxygen species, and associates with potassium efflux and cathepsin B release from lysosomes [226, 227]. Multiple inflammasomes, including NLRP3, NLRP1, NLRC2 and AIM2, have been implicated in PD. NLRP3 is the most thoroughly investigated inflammasome and seems to play a key role in driving the neuroinflammatory process [228]. Inflammasome involvement in PD pathogenesis has been investigated in both patients and animal models. Postmortem analysis of PD patient brains revealed increased expression of inflammasome components, including NLRP3, ASC and Caspase-1, in regions affected by the disease [229]. NLRP3 upregulation has been reported in activated PBMCs and in the plasma of patients with PD [230]. NLRP3 may act as a biomarker for neuroinflammation in PD and could be used to monitor disease progression [231]. In addition, NLRP3 downstream effectors, such as IL-18 and IL-1β, have been detected in the CSF and blood of PD patients [232]. Given the key link between NLRP3 and IL-1β maturation, the inflammasome likely represents a central connection between peripheral inflammation and the neurodegenerative damage characteristic of PD [223]. Additionally, a positive correlation was observed between high levels of α-syn in PD patient serum and increased inflammasome levels in PD patient PBMCs [230]. Transgenic mice overexpressing human α-syn accumulate α-syn aggregates and activate inflammasomes. These models explore how α-syn aggregation may trigger neuroinflammation through inflammasome pathways [233]. As noted above, multiple pathological hallmarks of PD are linked to the regulation and activation of the inflammasome complex. DA is the primary neurotransmitter involved in PD and affects PBMCs [234]. DA was identified as an endogenous modulator of the inflammasome, as it facilitates NLRP3 ubiquitinylation and degradation [235]. The MPTP rodent model of PD [123] demonstrated that NLRP3 inflammasome activation leads to neurodegeneration in DA neurons by impairing mitochondrial function and contributes to motor deficits [236]. In addition to the observed increase in NLRP3 triggering in the brain, MPTP-treated mice also exhibit alterations in NLRP3 expression within the liver and bone marrow-derived macrophages (BMDMs). Crucially, the downregulation of NLRP3, which specifically targets the liver in these mice, had a systemic effect. This reduction was concurrently associated with a decrease in inflammatory marker levels in both the serum (systemic circulation) and ultimately in the brain, suggesting a significant peripheral influence on central inflammation [237]. Studies using the 6-OHDA model of PD, which induces dopaminergic neuronal cell loss and motor symptoms in rats or mice, demonstrated activation of the NLRP3 inflammasome and the release of inflammatory cytokines, akin to what is observed in human PD [238]. Multiple animal studies have shown that inhibiting NLRP3 can prevent the development of PD phenotypes. Suppressing the inflammasome in MPTP-treated mice has been demonstrated to offer protection against neurodegeneration [239]. NLRP3−/− mice are less susceptible to MPTP than wild-type mice are and show reduced serum IL-1β and IL-18 levels [235]. Targeting inflammasomes could offer a potential therapeutic approach to mitigate neuroinflammation and slow the progression of PD. This suggested approach involves exploring small-molecule inhibitors of NLRP3, along with strategies that modulate upstream or downstream components of the inflammasome pathway [240]. However, more research is needed to fully understand the mechanisms involved and the potential for inflammasome-based therapies in PD treatment. Metabolites Numerous studies have identified alterations in the abundance of metabolites associated with peripheral inflammation in PD, highlighting dysfunctions in several metabolic pathways that could contribute to the pathogenesis of this disease (Fig. 2). For example, tryptophan metabolism via the kynurenine pathway has been extensively studied in PD, and significant alterations in the metabolites involved have been demonstrated, suggesting an imbalance toward neurotoxic and proinflammatory compounds. An increased ratio of 3-hydroxykyurenine (3-HK) to kynurenic acid was observed in the plasma of PD patients, especially in those with L-DOPA-induced dyskinesia, indicating a predominance of neurotoxic over neuroprotective metabolites. In addition, plasma levels of 3-HK were significantly greater (>100%), and those of 3-hydroxyanthranilic acid were reduced by 14% in PD patients compared with controls. These alterations were correlated with motor symptom severity and disease duration, suggesting a potential role of these metabolites as biomarkers of PD progression. Analyses of plasma and CSF samples revealed that changes in the levels of these metabolites in plasma reflect central alterations associated with neurodegeneration in PD patients [241, 242].Fig. 2Metabolic alterations associated with peripheral inflammation in PD patients. Each yellow central hub represents a metabolic pathway, with metabolites arranged radially around it. Node colours indicate their role in inflammation: blue = anti-inflammatory, purple = proinflammatory, grey = neutral. The diagram highlights how perturbations in tryptophan-kynurenine, purine and polyamine, lipid, amino acid, energy/redox, and gut microbiota-derived pathways contribute to systemic inflammation and disease progression in PD Metabolic alterations associated with peripheral inflammation in PD patients. Each yellow central hub represents a metabolic pathway, with metabolites arranged radially around it. Node colours indicate their role in inflammation: blue = anti-inflammatory, purple = proinflammatory, grey = neutral. The diagram highlights how perturbations in tryptophan-kynurenine, purine and polyamine, lipid, amino acid, energy/redox, and gut microbiota-derived pathways contribute to systemic inflammation and disease progression in PD Furthermore, alterations in purine metabolism were also assessed in PD patients, highlighting significant dysfunctions that could contribute to disease pathogenesis. In this context, reduced levels of uric acid (UA) in the plasma and CSF have been associated with increased oxidative stress and peripheral inflammation in PD patients. In particular, the considerably lower serum UA levels reported in PD patients than in healthy controls support the hypothesis of decreased endogenous antioxidant capability in PD patients. While the study revealed that low UA is more likely a consequence rather than a direct cause of neurodegeneration, its constant relationship with PD supports the hypothesis that low UA contributes to an oxidative and inflammatory environment that may impair neuronal susceptibility and disease development [243]. In addition, a decrease in hypoxanthine and inosine has been observed in the plasma of PD patients, indicating a dysfunction in purine recycling. These metabolic changes were also confirmed in CSF, where UA, hypoxanthine, and inosine levels were significantly lower in PD than in control patients [243]. Concurrently, a study investigating metabolic alterations in PD via blood plasma metabolomics reported increased levels of hypoxanthine, xanthine and UA [244]. Although alterations in metabolites associated with purine metabolism in PD are still debated due to inconsistent reports associated with disease progression, dysfunction of purine metabolism may play a significant role in the pathogenesis of PD by enhancing the oxidative stress and inflammatory processes that drive neurodegeneration. Purine metabolites such as UA, inosine, and hypoxanthine are essential for maintaining redox balance and cellular energy homeostasis, with UA acting as a major endogenous antioxidant and other purines supporting ATP production. Putatively, their reduced levels in the serum and CSF of PD patients suggest a disruption of this metabolic network, leading to weakened antioxidant defences, mitochondrial dysfunction, and increased vulnerability of DA neurons in the SN. Hence, altered purine metabolism may contribute to disease progression and represent a promising source of biomarkers reflecting underlying pathogenic mechanisms. Modifications in lipid metabolism have been observed in patients with PD, highlighting a possible association with peripheral inflammation. Specifically, PD patients have significantly lower levels of total cholesterol (TC), low-density lipoprotein (LDL) and triglycerides (TGs) than healthy controls do [245, 246]. These lipid changes were accompanied by increased levels of C-reactive protein (CRP) and circulating monocytes in the peripheral blood of PD patients, suggesting an association between lipid dysfunction and peripheral inflammation in PD patients. The observed changes in lipid metabolism in PD patients, characterized by low cholesterol and triglyceride levels as well as heightened inflammatory markers, possibly corroborate the relationship between lipid dysfunction and peripheral inflammation, supporting the notion that systemic metabolic abnormalities may contribute to PD pathogenesis and may be useful biomarkers for monitoring disease diagnosis and progression. Importantly, alterations in metabolites derived from the gut microbiota have been associated with PD, suggesting a role of gut dysbiosis in disease-related peripheral inflammation. Specifically, elevated plasma levels of hippuric acid (HA), a metabolite derived from microbial metabolism, were observed in patients with PD compared with healthy controls. PD patients have significantly increased plasma levels of HA, indole-3-propionic acid (PAH) and secondary bile acids, such as deoxycholic acid (DCA) and glycodeoxycholic acid (GDCA) [247]. After adjustment for age and sex, the plasma levels of HA (odds ratio (OR) 3.21, p < 0.001), PAH (OR 2.59, p = 0.031) and GDCA (OR 2.82, p = 0.036) were found to be associated with positive PD status. In addition, the levels of these microbial metabolites are associated with the relative abundance of proinflammatory gut bacteria, which is consistent with an interaction between gut dysbiosis and systemic inflammation in PD [247]. These observations strengthen the evidence that gut microbiota-derived metabolites are closely linked to PD-associated peripheral inflammation. As a result, these microbial metabolites not only shed light on the gut-immune axis in PD pathogenesis but also provide potential non-invasive biomarkers for disease diagnosis, stratification, and progression monitoring. Other studies highlighted alterations in the plasma levels of itaconate and cysteine-S-sulfate in PD patients. Metabolomics studies revealed that patients with PD have significantly reduced plasma levels of itaconate, a metabolite known for its anti-inflammatory properties. Itaconate is produced by activated macrophages and acts by inhibiting the NLRP3-linked inflammatory response, thus contributing to its modulation. The decrease in itaconate levels in PD patients could reflect an impairment of the immune system’s ability to control inflammation, promoting a proinflammatory environment that contributes to neurodegeneration [248]. In parallel, an increase in plasma levels of cysteine-S-sulfate has been observed in PD patients. This metabolite acts as an agonist of the N-methyl-D-aspartate (NMDA) receptor, and its increase can lead to excessive activation of such receptors, causing increased calcium entry into neuronal cells and consequently neuronal damage through excitotoxicity mechanisms. In addition, cysteine-S-sulfate levels increase as the disease progresses, suggesting a correlation between this metabolite and PD progression [249, 250]. This evidence suggests that alterations in itaconate and cysteine-S-sulfate levels could serve as potential biomarkers for the diagnosis and progression of PD and provide insights for the development of new therapeutic strategies aimed at modulating inflammation and excitotoxicity in the context of PD. Moreover, several metabolites in the plasma of PD patients are significantly altered compared with those in the plasma of healthy controls [251]. The study highlighted 14 metabolites with significantly altered levels in PD patients, and among these, 6 metabolites were particularly effective in distinguishing PD patients from controls, achieving an area under the curve (AUC) of 0.975 with 92% accuracy. The identified metabolites were L-3-methoxytyrosine (3-OMD), aconitic acid, L-methionine, 13-docosenamide (erucamide), HA and 9,12-octadecadienoic acid (linoleic acid). Additionally, the study revealed other metabolites with significant changes: taurine and ribonic acid, which were increased in PD patients (fold change ≈2.8 and 3.2, respectively), suggesting alterations in bile acid metabolism and potential disruptions in the pentose phosphate pathway; α-hydroxybutyric acid (α-HB), which was lower in PD patients, may reflect changes in glutathione metabolism and the oxidative stress response. Overall, these metabolic alterations point toward disturbances in amino acid metabolism, energy production pathways such as the tricarboxylic acid (TCA) cycle, fatty acid metabolism, and mitochondrial function in PD patients. Crucially, the identified metabolite panel demonstrated high discriminative power, underscoring its potential to enhance the diagnostic accuracy of PD. Furthermore, Serrano-Marín et al. investigated metabolic alterations in the aqueous humor of PD patients compared with controls [252]. This 2023 study revealed significant alterations in the levels of arginine-linked metabolites, citrulline, polyamines, and biogenic amines in the aqueous humor of PD patients. These changes may reflect disruptions in nitric oxide production and urea cycle function, cell proliferation and differentiation processes and mitochondrial physiology. In 2022, Galper et al. identified several lipid metabolites with altered levels in PD patients compared with controls [253]. In particular, when the serum and CSF of PD patients were compared with those of controls, altered levels of sphingolipids (e.g., sphingomyelins and ceramides), phosphatidylcholines, phosphatidylethanolamines and docosahexaenoic acid (DHA) were observed. The findings of this study could be useful for identifying and defining specific lipid patterns that might serve as biomarkers for this disease. Other studies revealed higher levels of itaconate and metabolites such as p-cresol sulfate, p-cresol glucuronide and phenylacetyl-L-glutamine in PD patients than in controls, suggesting potential alterations in inflammatory responses [254, 255]. Thus, the reported metabolic alterations in PD highlight profound changes in lipid homeostasis and immune-metabolic pathways. Dysregulated sphingolipids, phospholipids, and DHA point to disrupted membrane integrity and neuronal signalling, whereas changes in itaconate and gut microbiota-derived metabolites suggest an imbalance in inflammatory responses. Furthermore, reduced levels of inosine and urate may weaken endogenous anti-inflammatory and antioxidant defences, potentially exacerbating disease progression. Overall, according to published data, peripheral inflammation and neurodegenerative processes in PD are intimately linked to systemic metabolic changes found in plasma, serum, CSF, and other biofluids. In addition to reflecting the oxidative stress and inflammation linked to illness, the persistent dysregulation of pathways involving amino acids, purines, lipids, immune-modulatory metabolites, and chemicals generated from the gut microbiome also represents central neurodegenerative alterations. These results support the promise of metabolite-based signatures as readily available and minimally invasive biomarkers for PD diagnosis, patient classification, and disease progression tracking from a clinical standpoint. Furthermore, targeting immune-metabolic dysfunctions may provide new opportunities for tailored therapeutic interventions aimed at reducing inflammation, restoring redox balance, and limiting neuronal vulnerability in PD, given the strong correlations between specific metabolic changes and symptom severity or disease duration. Exosomes and PD Prokaryotic and eukaryotic cells release extracellular vesicles (EVs) in response to specific external signals. EVs are divided into three subgroups, namely, exosomes, microparticles (MPs)/microvesicles (MVs), and apoptotic bodies, on the basis of their diameter, source, and biochemical markers. MPs/MVs (100–1000 nm) are released by budding of the plasma membrane, and exosomes (100–200 nm) are generated from the endosomal/multivesicular body (MVB) system and accumulate inside the cell prior to their release; moreover, during the final phase of the apoptotic process, cells release apoptotic bodies (1000–5000 nm) [256]. Under oxidative stress conditions, as observed in neurodegenerative disorders such as PD, the loss of lipid bilayer asymmetry may occur through the translocation of phosphatidylserine to the outer membrane leaflet [257]. Oxidative modification and subsequent dysfunction of flippase hinder the restoration of membrane asymmetry, leading to the local accumulation of negative charges and outward membrane blebbing. This process can result in the release of EVs containing oxidized components (including flippase) [258], thereby representing a potential mechanism of EV formation in PD. Crosstalk between glia and neurons in the CNS is important for many biological functions, including brain development, homeostasis maintenance, and neural circuit formation. In addition to traditional direct cell-to-cell contact, cells in the CNS can communicate through the paracrine action of secreted molecules or through the release and reception of extracellular vesicles, especially exosomes [259, 260]. The uptake of EVs by glial cells and neurons can occur through specific membrane receptors, such as the phosphatidylserine receptor T-cell immunoglobulin and mucin domain containing 4 (TIM4), which may contribute to cellular activation and modulation of neuroinflammatory responses [261, 262]. Exosomes may pass through the BBB bidirectionally from the bloodstream to the brain parenchyma and vice versa. They play an important role in brain-peripheral communication in physiology and pathophysiology. Exosomes are widely present in CSF and peripheral body fluids, and they play a potential role in several physiological functions, such as signal transduction between cells, the transfer of pathogens, and the removal of cell debris. They are essential for the maintenance of nervous system development and function. Exosomes are released by all the cells of the CNS; indeed, exosomes from neurons can regulate synapses, neurodevelopment, neuroimmunity, and neuromuscular junctions. In contrast, exosomes released by oligodendrocytes, Schwann cells, astrocytes, microglia, mesenchymal stromal stem cells, epithelial cells, and embryonic CSF sources can maintain the normal functions of neurons and neural stem cells [263]. In the monomeric physiological state, α-syn is composed of 140 amino acids; under pathological conditions, such as oxidative stress or posttranslational modifications, it may be altered, resulting in an aberrant β-folding structure [264, 265]. In recent years, many studies have detected the two forms of α-syn (monomeric and oligomeric) [266–268] among the cargo inside exosomes. Exosomes can induce α-syn spread among neurons, which promotes neurotoxicity. Exosomes from neurons can carry α-syn into microglia and decrease microglial autophagy [269]. Moreover, exosomes may transfer oligomers of α-syn, which are more effective than α-syn monomers are, confirming the important role of exosomes in the spread of α-syn [270]. Moreover, Stuendl et al. reported that the exosomes present in the CSF of PD patients exhibit α-syn aggregate formation; in contrast, the exosomes from the control group contained monomers [271]. Huang et al. demonstrated that in SNCAA53T transgenic PD mice, exosomes from PD patients positive for L1CAM promoted the seeding of α-syn and neuron loss [272]. This research confirmed that exosomes may create a microenvironment that increases α-syn aggregation and induces pathological α-syn production and spread. Neuronal EVs are emerging as novel biomarkers for neurodegenerative disorders. Different studies have reported that the number of neuronal EVs containing α-syn is greater in patients with early and advanced forms of the disease than in healthy individuals [273, 274]. In PD patients, EVs enriched with astrocyte markers from plasma present higher levels of total α-syn and α-syn aggregates than healthy controls do [275]. Additionally, EVs isolated from the serum, CSF, and brain lysates of patients with PD contain aggregates of α-syn [276]. These vesicles can transfer the aggregated protein to healthy DA neurons, leading to the development of PD pathology both in vitro and in vivo [277–280]. In addition, other studies have demonstrated that exosomes can carry several types of RNA (including miRNAs), nuclear DNA and mitochondrial DNA and that exosomal miRNAs can be transmitted from cell to cell, modifying the genetic program of target cells and promoting the progression of PD [281]. A study from 2019 demonstrated that exosomes present in the plasma of PD patients contain elevated levels of miR-137, which contributes to the development of PD through oxidative stress; the upregulation of antioxidant gene 1 (OXR1) reduces miR-137 and induces neuroprotection [282]. Moreover, exosomes from neurons of PD patients contain miR-155, which is a mediator of the α-syn-induced inflammatory response [283, 284]. In contrast, exosomes isolated from differentiated DA neurons can reduce the levels of IL-6, IL-1β, TNF-α, and ROS in an in vitro PD model [285]. These findings confirm that exosomes containing specific miRNAs are closely related to PD. In a recent review, Huang et al. described all the PD biomarkers contained in exosomes present in different biological fluids, such as blood, saliva, and CSF [286]. Exosomes have the ability to cross the BBB and selectively modulate their cargo, and they are considered promising therapeutic targets. The BBB exhibits highly selective permeability that effectively limits the passage of large molecules and almost all small molecules from other organs to the brain. Owing to their low toxicity and immunological inertness, exosomes may be able to avoid rapid drug clearance by the host immune system [287]. Exosomes are proposed to be nanoscavengers that transport various cargo, such as RNA, miRNA, and drugs such as quercetin and curcumin [288, 289]. These studies have investigated the use of exosomes as effective brain-targeted drug delivery systems to increase drug efficacy and reduce side effects. Exosomes engineered to carry catalase were shown to mitigate neural inflammation and enhance neural viability in PD models [290]. Additionally, Qu et al. loaded DA into plasma-derived exosomes and subsequently intravenously injected the DA-loaded exosomes into a PD mouse model. DA-loaded exosomes were able to cross the BBB and were delivered to the striatum and SNpc, demonstrating enhanced therapeutic efficacy and reduced toxicity [291]. In addition, exosomes may deliver small interfering RNAs (siRNAs) that target α-syn, reducing its levels and ameliorating PD symptoms [292]. Moreover, mesenchymal stem cell (MSC)-derived exosomes, through the delivery of beneficial microRNAs, protect DA neurons and reduce neuroinflammation in PD models [293]. However, increasing exosome loading efficiency and developing exosome-based diagnostic and therapeutic tools will require additional studies (Fig. 3).Fig. 3Exosome-mediated mechanisms in PD. Exosomes derived from central and peripheral sources can cross the BBB via specific surface proteins, enabling bidirectional shuttling between the circulation and the brain. In PD, exosomes carrying α-syn oligomers and microRNAs, such as miRNA 137 (miR-137), contribute to neuroinflammation, neuronal dysfunction, and disease propagation. Conversely, engineered exosomes can deliver therapeutic cargos such as siRnas designed to reduce α-syn expression, thereby mitigating neurodegeneration and restoring cellular homeostasis Exosome-mediated mechanisms in PD. Exosomes derived from central and peripheral sources can cross the BBB via specific surface proteins, enabling bidirectional shuttling between the circulation and the brain. In PD, exosomes carrying α-syn oligomers and microRNAs, such as miRNA 137 (miR-137), contribute to neuroinflammation, neuronal dysfunction, and disease propagation. Conversely, engineered exosomes can deliver therapeutic cargos such as siRnas designed to reduce α-syn expression, thereby mitigating neurodegeneration and restoring cellular homeostasis Therapeutic targeting of peripheral immune pathways in PD: current advances and translational outlook In addition to their mechanistic implications, the immune pathways discussed throughout this review have increasingly emerged as actionable therapeutic targets in PD. In recent years, a growing number of preclinical and clinical studies have shifted their attention toward strategies aimed at modulating peripheral immune dysfunction, with the goal of attenuating neuroinflammation, limiting α-syn-driven pathology, and ultimately slowing disease progression. As summarized in Table 3, current immune- and inflammation-oriented therapeutic approaches encompass multiple, partially convergent strategies. These include direct anti-inflammatory interventions targeting proinflammatory cytokine signalling and NLRP3 inflammasome activation; inhibition of LRRK2 kinase activity to restrain monocyte and microglial hyperactivation; immunometabolic modulation through GLP-1 receptor agonists; microbiota-targeted interventions aimed at reducing gut-driven immune priming and barrier dysfunction; and exosome-based delivery systems that exploit intercellular transfer mechanisms to reduce the α-syn burden and oxidative stress. Importantly, these approaches reflect a paradigm shift from symptomatic treatment toward disease-modifying strategies that specifically address peripheral immune abnormalities contributing to central neurodegeneration. Current research is exploring sophisticated strategies such as the “molecular decoy” CS2, which is designed to shield mitochondria from α-syn-mediated damage [297]. Similarly, the repurposing of anti-inflammatory agents such as aspirin has demonstrated preclinical efficacy in preserving DA neurons [298].Table 3Immune- and inflammation-oriented therapeutic strategies in PD (I, interventional; P, preclinical)Therapeutic strategyImmune abnormalityto targetStudy typeClinical phaseMain outcomeReferencesAnti-inflammatory therapeuticsInflammatory cytokines signalling (TNF-α, IL-1β, IL-6); NLRP3-mediated inflammasome activationP, IPhase 1 and 2Reduced inflammation/neuroinflammation and α-syn pathology (disease-modifying treatments)[294, 295]LRRK2 kinase inhibitorsLRRK2-dependent monocyte and microglial hyperactivationIPhase 1 and 2Safety, target engagement, slowing of clinical progression (disease-modifying treatments)[295]GLP-1 receptor agonistsImmuno-metabolic imbalance driving chronic inflammation, microglial activation, and cytokine overproductionIPhase 1, 2 and 3Slowing of clinical progression, reduced inflammation (disease-modifying treatments)[295, 296]Microbiota-targeted interventionsGut microbiota-driven immune priming, barrier dysfunction, and chronic low-grade inflammationIPhase 1, 2 and 3Reduction of intestinal permeability, changes in inflammatory markers and metabolites, prevention of α-syn “prion-like” spread(disease-modifying treatments and symptomatic treatments)[295, 296]Exosome-based delivery systemsα-syn accumulation and oxidative stress in immune-neural cellsP-Targeted delivery of therapeutic agents, such as siRNA for α-syn silencing or antioxidant enzymes[290]Molecular decoyMitochondria α-syn mediated damageP-Disease-modifying treatments[297] Table 3Immune- and inflammation-oriented therapeutic strategies in PD (I, interventional; P, preclinical)Therapeutic strategyImmune abnormalityto targetStudy typeClinical phaseMain outcomeReferencesAnti-inflammatory therapeuticsInflammatory cytokines signalling (TNF-α, IL-1β, IL-6); NLRP3-mediated inflammasome activationP, IPhase 1 and 2Reduced inflammation/neuroinflammation and α-syn pathology (disease-modifying treatments)[294, 295]LRRK2 kinase inhibitorsLRRK2-dependent monocyte and microglial hyperactivationIPhase 1 and 2Safety, target engagement, slowing of clinical progression (disease-modifying treatments)[295]GLP-1 receptor agonistsImmuno-metabolic imbalance driving chronic inflammation, microglial activation, and cytokine overproductionIPhase 1, 2 and 3Slowing of clinical progression, reduced inflammation (disease-modifying treatments)[295, 296]Microbiota-targeted interventionsGut microbiota-driven immune priming, barrier dysfunction, and chronic low-grade inflammationIPhase 1, 2 and 3Reduction of intestinal permeability, changes in inflammatory markers and metabolites, prevention of α-syn “prion-like” spread(disease-modifying treatments and symptomatic treatments)[295, 296]Exosome-based delivery systemsα-syn accumulation and oxidative stress in immune-neural cellsP-Targeted delivery of therapeutic agents, such as siRNA for α-syn silencing or antioxidant enzymes[290]Molecular decoyMitochondria α-syn mediated damageP-Disease-modifying treatments[297] Immune- and inflammation-oriented therapeutic strategies in PD (I, interventional; P, preclinical) Reduction of intestinal permeability, changes in inflammatory markers and metabolites, prevention of α-syn “prion-like” spread (disease-modifying treatments and symptomatic treatments) While several interventions have progressed to early- and mid-stage clinical trials, their translational success will likely depend on improved patient stratification based on immune and metabolic profiles, as well as the identification of reliable peripheral biomarkers to monitor target engagement and therapeutic response. From a translational perspective, the clinical feasibility of targeting peripheral immune pathways critically depends on the identification of robust and accessible biomarkers. Among the peripheral immune markers discussed, circulating cytokine profiles, inflammasome-related components in peripheral blood mononuclear cells, monocyte subset composition, and immune-metabolic signatures represent the most immediately applicable candidates, given their accessibility and compatibility with routine clinical sampling. Future research efforts should therefore prioritize longitudinal, immune-stratified cohort studies, harmonize analytical methodologies, and integrate peripheral immune markers into adaptive clinical trial designs. The integration of multiomics data and quantum computing promises to identify unique “signatures” capable of predicting individual disease trajectories. Such approaches will be essential to define patient subgroups most likely to benefit from immune-targeted interventions and to establish peripheral immune markers as actionable tools for disease monitoring and precision medicine in PD. Conclusions The latest scientific findings, in summary, undoubtedly indicate that neuroinflammation is a key factor in the development of PD. Inflammation is not merely a bystander but an essential catalyst driving disease pathogenesis and progression. Central to this process is the role of the inflammatory milieu as a primary driver of α-syn propagation. This mechanism operates through a self-perpetuating vicious cycle: misfolded α-syn aggregates originating in peripheral tissues, such as the gastrointestinal tract, skin, and olfactory system, or packaged into exosomes reaching the periphery by glymphatic flow, trigger the activation of circulating innate immune cells, particularly monocytes, resulting in cytokine overproduction, inflammasome engagement, metabolic reprogramming, and altered intercellular communication, leading to an inflammatory cascade that promotes barrier dysfunction and immune-neural crosstalk. Once in the parenchyma, cytokines are taken up by both neurons and microglia; the latter become activated, leading to the expulsion of further inflammatory cytokines, nitric oxide and ROS that, in turn, damage neurons in the SNPC, leading to death. The detritus released from these dying neurons, in turn, binds to other neurons and microglia, repeating the same processes that lead to further neuronal death [6]. This bidirectional peripheral-central interaction generates a self-sustaining feedforward loop that couples immune dysregulation to progressive dopaminergic neuron loss. The neuroinflammatory drive is further exacerbated by mitochondrial dysfunction, whereby the interplay between inflammation and protein accumulation leads to energetic failure, depriving neurons of the metabolic resources required for survival and ultimately accelerating the degenerative process. The elucidation of these pathways has profound translational implications, particularly for early diagnosis and therapeutic intervention. In the diagnostic realm, the Systemic Immune-Inflammation Index has emerged as a compelling peripheral biomarker capable of distinguishing PD patients from healthy individuals with moderate accuracy. Translating these insights into clinical practice remains challenging. More evidence needs to be gathered to establish causality rather than mere association with inflammation, as cross-sectional studies cannot definitively confirm that inflammation precedes clinical onset. Furthermore, the safety profiles of chronic immunosuppression, including increased infection risk and systemic side effects, preclude its widespread adoption. Addressing inter-individual variability and validating these findings through large-scale, longitudinal human trials will be essential to bridge the gap between preclinical discovery and the realization of disease-modifying therapies in PD.